{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:49:05Z","timestamp":1793969345349,"version":"4.8.0"},"reference-count":47,"publisher":"Harborside Press, LLC","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:p>\n                    Bladder cancer, the sixth most common cancer in the United States, is most commonly of the urothelial carcinoma histologic subtype. The clinical spectrum of bladder cancer is divided into 3 categories that differ in prognosis, management, and therapeutic aims: (1) non\u2013muscle-invasive bladder cancer (NMIBC); (2) muscle invasive, nonmetastatic disease; and (3) metastatic bladder cancer. These NCCN Guidelines Insights detail recent updates to the NCCN Guidelines for Bladder Cancer, including changes in the fifth edition of the\n                    <jats:italic>WHO Classification of Tumours: Urinary and Male Genital Tumours<\/jats:italic>\n                    and how the NCCN Guidelines aligned with these updates; new and emerging treatment options for bacillus Calmette-Gu\u00e9rin (BCG)\u2013unresponsive NMIBC; and updates to systemic therapy recommendations for advanced or metastatic disease.\n                  <\/jats:p>","DOI":"10.6004\/jnccn.2024.0024","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T08:40:37Z","timestamp":1715848837000},"page":"216-225","source":"Crossref","is-referenced-by-count":273,"title":["Bladder Cancer, Version 3.2024"],"prefix":"10.6004","volume":"22","author":[{"given":"Thomas W.","family":"Flaig","sequence":"first","affiliation":[{"name":"University of Colorado Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe E.","family":"Spiess","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Abern","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute at the University of Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick","family":"Bangs","sequence":"additional","affiliation":[{"name":"Patient Advocate"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark K.","family":"Buyyounouski","sequence":"additional","affiliation":[{"name":"Stanford Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Chan","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam S.","family":"Chang","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Chang","sequence":"additional","affiliation":[{"name":"The UChicago Medicine Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence","family":"Friedlander","sequence":"additional","affiliation":[{"name":"UCSF Helen Diller Family Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Greenberg","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khurshid A.","family":"Guru","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry W.","family":"Herr","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Hoffman-Censits","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hristos","family":"Kaimakliotis","sequence":"additional","affiliation":[{"name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar U.","family":"Kishan","sequence":"additional","affiliation":[{"name":"UCLA Jonsson Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilajit","family":"Kundu","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subodh M.","family":"Lele","sequence":"additional","affiliation":[{"name":"Fred & Pamela Buffett Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronac","family":"Mamtani","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center at the University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar Y.","family":"Mian","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Michalski","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Montgomery","sequence":"additional","affiliation":[{"name":"University of Michigan Rogel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamta","family":"Parikh","sequence":"additional","affiliation":[{"name":"UC Davis Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Patterson","sequence":"additional","affiliation":[{"name":"St. Jude Children\u2019s Research Hospital\/The University of Tennessee Health Science Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Peyton","sequence":"additional","affiliation":[{"name":"O\u2019Neal Comprehensive Cancer Center at UAB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R.","family":"Plimack","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Preston","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Brigham and Women\u2019s Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Richards","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wade J.","family":"Sexton","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene O.","family":"Siefker-Radtke","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Stewart","sequence":"additional","affiliation":[{"name":"UC San Diego Moores Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debasish","family":"Sundi","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Tollefson","sequence":"additional","affiliation":[{"name":"Mayo Clinic Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Tward","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute at the University of Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L.","family":"Wright","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly J.","family":"Cassara","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Gurski","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"CA Cancer J Clin","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel RL","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin 2024;74:12\u201349."},{"key":"B2","article-title":"Bladder cancer: bladder cancer","unstructured":"SEER. Bladder cancer: bladder cancer. Accessed February 8, 2024. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html"},{"key":"B3","series-title":"Am Fam Physician","first-page":"507","article-title":"Bladder cancer: diagnosis and treatment","volume":"96","author":"DeGeorge KC","year":"2017","unstructured":"DeGeorge KC, Holt HR, Hodges SC. Bladder cancer: diagnosis and treatment. Am Fam Physician 2017;96:507\u2013514."},{"key":"B4","series-title":"Medicine (Baltimore)","first-page":"e8588","article-title":"Diabetes mellitus and the risk of bladder cancer: a PRISMA-compliant meta-analysis of cohort studies","volume":"96","author":"Xu Y","year":"2017","unstructured":"Xu Y, Huo R, Chen X,  Diabetes mellitus and the risk of bladder cancer: a PRISMA-compliant meta-analysis of cohort studies. Medicine (Baltimore) 2017;96:e8588."},{"key":"B5","series-title":"Eur Urol","first-page":"96","article-title":"Bladder cancer incidence and mortality: a global overview and recent trends","volume":"71","author":"Antoni S","year":"2017","unstructured":"Antoni S, Ferlay J, Soerjomataram I,  Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol 2017;71:96\u2013108."},{"key":"B6","series-title":"Urol Oncol","first-page":"199","article-title":"Bladder cancer risk from occupational and environmental exposures","volume":"30","author":"Kiriluk KJ","year":"2012","unstructured":"Kiriluk KJ, Prasad SM, Patel AR,  Bladder cancer risk from occupational and environmental exposures. Urol Oncol 2012;30:199\u2013211."},{"key":"B7","series-title":"Medicine (Baltimore)","first-page":"e11596","article-title":"Association of metformin intake with bladder cancer risk and oncologic outcomes in type 2 diabetes mellitus patients: a systematic review and meta-analysis","volume":"97","author":"Hu J","year":"2018","unstructured":"Hu J, Chen JB, Cui Y,  Association of metformin intake with bladder cancer risk and oncologic outcomes in type 2 diabetes mellitus patients: a systematic review and meta-analysis. Medicine (Baltimore) 2018;97:e11596."},{"key":"B8","series-title":"J Clin Oncol","first-page":"406","article-title":"Cancer susceptibility mutations in patients with urothelial malignancies","volume":"38","author":"Carlo MI","year":"2020","unstructured":"Carlo MI, Ravichandran V, Srinavasan P,  Cancer susceptibility mutations in patients with urothelial malignancies. J Clin Oncol 2020;38:406\u2013414."},{"key":"B9","series-title":"Rev Urol","first-page":"31","article-title":"Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history","volume":"10","author":"Pasin E","year":"2008","unstructured":"Pasin E, Josephson DY, Mitra AP,  Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Rev Urol 2008;10:31\u201343."},{"key":"B10","series-title":"Can Urol Assoc J","first-page":"S193","article-title":"Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer","volume":"3","author":"Chalasani V","year":"2009","unstructured":"Chalasani V, Chin JL, Izawa JI. Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer. Can Urol Assoc J 2009;3(Suppl 4):S193\u2013198."},{"key":"B11","series-title":"Eur Urol","first-page":"458","article-title":"The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-part A: renal, penile, and testicular tumours","volume":"82","author":"Moch H","year":"2022","unstructured":"Moch H, Amin MB, Berney DM,  The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-part A: renal, penile, and testicular tumours. Eur Urol 2022;82:458\u2013468."},{"key":"B12","series-title":"Eur Urol","first-page":"469","article-title":"The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs-part B: prostate and urinary tract tumors","volume":"82","author":"Netto GJ","year":"2022","unstructured":"Netto GJ, Amin MB, Berney DM,  The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs-part B: prostate and urinary tract tumors. Eur Urol 2022;82:469\u2013482."},{"key":"B13","series-title":"Urol Oncol","first-page":"15","article-title":"The value and limitations of urothelial bladder carcinoma molecular classifications to predict oncological outcomes and cancer treatment response: a systematic review and meta-analysis","volume":"39","author":"Kardoust Parizi M","year":"2021","unstructured":"Kardoust Parizi M, Margulis V, Comp\u00e9rat EM,  The value and limitations of urothelial bladder carcinoma molecular classifications to predict oncological outcomes and cancer treatment response: a systematic review and meta-analysis. Urol Oncol 2021;39:15\u201333."},{"key":"B14","series-title":"J Urol","first-page":"1129","article-title":"A systematic review and meta-analysis of variant histology in urothelial carcinoma of the bladder treated with radical cystectomy","volume":"204","author":"Mori K","year":"2020","unstructured":"Mori K, Abufaraj M, Mostafaei H,  A systematic review and meta-analysis of variant histology in urothelial carcinoma of the bladder treated with radical cystectomy. J Urol 2020;204:1129\u20131140."},{"key":"B15","series-title":"Eur Urol Oncol","first-page":"625","article-title":"What is the prognostic and clinical importance of urothelial and nonurothelial histological variants of bladder cancer in predicting oncological outcomes in patients with muscle-invasive and metastatic bladder cancer? A European Association of Urology muscle invasive and metastatic bladder cancer guidelines panel systematic review","volume":"2","author":"Veskim\u00e4e E","year":"2019","unstructured":"Veskim\u00e4e E, Espinos EL, Bruins HM,  What is the prognostic and clinical importance of urothelial and nonurothelial histological variants of bladder cancer in predicting oncological outcomes in patients with muscle-invasive and metastatic bladder cancer? A European Association of Urology muscle invasive and metastatic bladder cancer guidelines panel systematic review. Eur Urol Oncol 2019;2:625\u2013642."},{"key":"B16","series-title":"Pathologica","first-page":"32","article-title":"News in the classification of WHO 2022 bladder tumors","volume":"115","author":"Raspollini MR","year":"2022","unstructured":"Raspollini MR, Comp\u00e9rat EM, Lopez-Beltran A,  News in the classification of WHO 2022 bladder tumors. Pathologica 2022;115:32\u201340."},{"key":"B17","series-title":"J Urol","first-page":"1021","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang SS","year":"2016","unstructured":"Chang SS, Boorjian SA, Chou R,  Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline. J Urol 2016;196:1021\u20131029."},{"key":"B18","series-title":"J Urol","first-page":"180","article-title":"Intracavitary bacillus Calmette- Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales A","year":"1976","unstructured":"Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette- Guerin in the treatment of superficial bladder tumors. J Urol 1976;116:180\u2013183."},{"key":"B19","series-title":"J Urol","first-page":"90","article-title":"Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta- analysis of comparative studies on recurrence and toxicity","volume":"169","author":"B\u00f6hle A","year":"2003","unstructured":"B\u00f6hle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta- analysis of comparative studies on recurrence and toxicity. J Urol 2003;169:90\u201395."},{"key":"B20","series-title":"Urology","first-page":"1216","article-title":"Can intravesical bacillus Calmette-Gu\u00e9rin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials","volume":"67","author":"Han RF","year":"2006","unstructured":"Han RF, Pan JG. Can intravesical bacillus Calmette-Gu\u00e9rin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006;67:1216\u20131223."},{"key":"B21","series-title":"BJU Int","first-page":"209","article-title":"A systematic review of intravesical bacillus Calmette-Gu\u00e9rin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer","volume":"88","author":"Shelley MD","year":"2001","unstructured":"Shelley MD, Kynaston H, Court J,  A systematic review of intravesical bacillus Calmette-Gu\u00e9rin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 2001;88:209\u2013216."},{"key":"B22","series-title":"BJU Int","first-page":"485","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials","volume":"93","author":"Shelley MD","year":"2004","unstructured":"Shelley MD, Wilt TJ, Court J,  Intravesical bacillus Calmette-Gu\u00e9rin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 2004;93:485\u2013490."},{"key":"B23","series-title":"Eur Urol","first-page":"247","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstr\u00f6m PU","year":"2009","unstructured":"Malmstr\u00f6m PU, Sylvester RJ, Crawford DE,  An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247\u2013256."},{"key":"B24","series-title":"J Oncol Pract","first-page":"92","article-title":"Adjuvant intravesical bacillus Calmette-Gu\u00e9rin therapy and survival among elderly patients with non-muscle-invasive bladder cancer","volume":"9","author":"Spencer BA","year":"2013","unstructured":"Spencer BA, McBride RB, Hershman DL,  Adjuvant intravesical bacillus Calmette-Gu\u00e9rin therapy and survival among elderly patients with non-muscle-invasive bladder cancer. J Oncol Pract 2013;9:92\u201398."},{"key":"B25","series-title":"Eur Urol","first-page":"260","article-title":"Long-term efficacy of maintenance bacillus Calmette-Gu\u00e9rin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up","volume":"56","author":"J\u00e4rvinen R","year":"2009","unstructured":"J\u00e4rvinen R, Kaasinen E, Sankila A,  Long-term efficacy of maintenance bacillus Calmette-Gu\u00e9rin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. Eur Urol 2009;56:260\u2013265."},{"key":"B26","series-title":"Cochrane Database Syst Rev","first-page":"CD011935","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin versus mitomycin C for Ta and T1 bladder cancer","volume":"1","author":"Schmidt S","year":"2020","unstructured":"Schmidt S, Kunath F, Coles B,  Intravesical bacillus Calmette-Gu\u00e9rin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database Syst Rev 2020;1:CD011935."},{"key":"B27","article-title":"BCG shortage notice","unstructured":"American Urological Association BCG shortage notice. Accessed February 8, 2024. Available at: https:\/\/www.auanet.org\/bcg- shortage-notice"},{"key":"B28","article-title":"Prescribing information for TICE BCG live, for intravesical use","year":"2009","unstructured":"Prescribing information for TICE BCG live, for intravesical use. 2009. Accessed February 8, 2024. Available at: http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM163039.pdf"},{"key":"B29","series-title":"Eur Urol","first-page":"429","article-title":"Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trial","volume":"44","author":"van der Meijden AP","year":"2003","unstructured":"van der Meijden AP, Sylvester RJ, Oosterlinck W,  Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trial. Eur Urol 2003;44:429\u2013434."},{"key":"B30","series-title":"Lancet Oncol","first-page":"919","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar AV","year":"2021","unstructured":"Balar AV, Kamat AM, Kulkarni GS,  Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol 2021;22:919\u2013930."},{"key":"B31","series-title":"J Clin Oncol","first-page":"Abstract LBA442","article-title":"Pembrolizumab (pembro) monotherapy for patients (pts) with high-risk non\u2013muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette-Gu\u00e9rin (BCG): results from cohort B of the phase 2 KEYNOTE-057 trial","volume":"41","author":"Necchi A","year":"2023","unstructured":"Necchi A, Roumigui\u00e9 M, Esen AA,  Pembrolizumab (pembro) monotherapy for patients (pts) with high-risk non\u2013muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette-Gu\u00e9rin (BCG): results from cohort B of the phase 2 KEYNOTE-057 trial. J Clin Oncol 2023;41:Abstract LBA442."},{"key":"B32","series-title":"Lancet Oncol","first-page":"107","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian SA","year":"2021","unstructured":"Boorjian SA, Alemozaffar M, Konety BR,  Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol 2021;22:107\u2013117."},{"key":"B33","series-title":"J Urol","first-page":"Abstract MP16-01","article-title":"Efficacy of intravesical nadofaragene firadenovec for patients with carcinoma in situ (CIS), BCG-unresponsive non-muscle invasive bladder cancer (NMIBC): longer-term follow-up from the phase III trial","volume":"206","author":"Schuckman AK","year":"2021","unstructured":"Schuckman AK, Lotan Y, Boorjian SA,  Efficacy of intravesical nadofaragene firadenovec for patients with carcinoma in situ (CIS), BCG-unresponsive non-muscle invasive bladder cancer (NMIBC): longer-term follow-up from the phase III trial. J Urol 2021;206(Suppl 3):Abstract MP16-01."},{"key":"B34","series-title":"J Urol","first-page":"Abstract MP16-02","article-title":"Phase III trial of intravesical nadofaragene firadenovec in patients with high-grade, BCG-unresponsive, non-muscle invasive bladder cancer: two year follow-up in the Ta\/T1 cohort","volume":"206","author":"Lotan Y","year":"2021","unstructured":"Lotan Y, Schuckman AK, Boorjian SA,  Phase III trial of intravesical nadofaragene firadenovec in patients with high-grade, BCG-unresponsive, non-muscle invasive bladder cancer: two year follow-up in the Ta\/T1 cohort. J Urol 2021;206(Suppl 3):Abstract MP16-02."},{"key":"B35","series-title":"Ann Oncol","first-page":"S1224","article-title":"2407TiP SunRISe-3: TAR-200 plus cetrelimab (CET) or TAR-200 versus intravesical bacillus Calmette-Guerin (BCG) in patients (pts) with BCG-naive high-risk non-muscle-invasive bladder cancer (HR NMIBC)","volume":"34","author":"Necchi A","year":"2023","unstructured":"Necchi A, Catto JWF, Powles TB,  2407TiP SunRISe-3: TAR-200 plus cetrelimab (CET) or TAR-200 versus intravesical bacillus Calmette-Guerin (BCG) in patients (pts) with BCG-naive high-risk non-muscle-invasive bladder cancer (HR NMIBC). Ann Oncol 2023;34(Suppl 2):S1224."},{"key":"B36","series-title":"Urol Oncol","first-page":"440","article-title":"An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: interim results","volume":"36","author":"Packiam VT","year":"2018","unstructured":"Packiam VT, Lamm DL, Barocas DA,  An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: interim results. Urol Oncol 2018;36:440\u2013447."},{"key":"B37","series-title":"J Urol","first-page":"e408","article-title":"CORE1: phase 2 single arm study of CG0070 combined with pembrolizumab in patients with non muscle invasive bladder cancer unresponsive to bacillus Calmette-Guerin (BCG)","volume":"209","author":"Li R","year":"2023","unstructured":"Li R, Steinberg G, Uchio EM,  CORE1: phase 2 single arm study of CG0070 combined with pembrolizumab in patients with non muscle invasive bladder cancer unresponsive to bacillus Calmette-Guerin (BCG). J Urol 2023;209(Suppl 4):e408."},{"key":"B38","series-title":"NEJM Evid","first-page":"EVIDoa2200167","article-title":"IL-15 superagonist NAI in BCG-unresponsive non-muscle-invasive bladder cancer","volume":"2","author":"Chamie K","year":"2023","unstructured":"Chamie K, Chang SS, Kramolowsky E,  IL-15 superagonist NAI in BCG-unresponsive non-muscle-invasive bladder cancer. NEJM Evid 2023;2:EVIDoa2200167."},{"key":"B39","series-title":"J Clin Oncol","first-page":"Abstract 451","article-title":"Defining \u201cplatinum-ineligible\u201d patients with metastatic urothelial cancer (mUC)","volume":"37","author":"Gupta S","year":"2019","unstructured":"Gupta S, Sonpavde G, Grivas P,  Defining \u201cplatinum-ineligible\u201d patients with metastatic urothelial cancer (mUC). J Clin Oncol 2019;37:Abstract 451."},{"key":"B40","series-title":"J Natl Cancer Inst","first-page":"547","article-title":"Platinum ineligibility and survival outcomes in patients with advanced urothelial carcinoma receiving first-line treatment","volume":"116","author":"Gupta S","year":"2023","unstructured":"Gupta S, Andreev-Drakhlin A, Fajardo O,  Platinum ineligibility and survival outcomes in patients with advanced urothelial carcinoma receiving first-line treatment. J Natl Cancer Inst 2023;116:547\u2013554."},{"key":"B41","series-title":"N Engl J Med","first-page":"875","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles T","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S,  Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med 2024;390:875\u2013888."},{"key":"B42","series-title":"N Engl J Med","first-page":"1778","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden MS","year":"2023","unstructured":"van der Heijden MS, Sonpavde G, Powles T,  Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma. N Engl J Med 2023;389:1778\u20131789."},{"key":"B43","series-title":"N Engl J Med","first-page":"338","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot Y","year":"2019","unstructured":"Loriot Y, Necchi A, Park SH,  Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med 2019;381:338\u2013348."},{"key":"B44","series-title":"Lancet Oncol","first-page":"248","article-title":"Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study","volume":"23","author":"Siefker-Radtke AO","year":"2022","unstructured":"Siefker-Radtke AO, Necchi A, Park SH,  Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. Lancet Oncol 2022;23:248\u2013258."},{"key":"B45","series-title":"N Engl J Med","first-page":"1961","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot Y","year":"2023","unstructured":"Loriot Y, Matsubara N, Park SH,  Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. N Engl J Med 2023;389:1961\u20131971."},{"key":"B46","series-title":"Ann Oncol","first-page":"107","article-title":"Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial","volume":"35","author":"Siefker-Radtke AO","year":"2024","unstructured":"Siefker-Radtke AO, Matsubara N, Park SH,  Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial. Ann Oncol 2024;35:107\u2013117."},{"key":"B47","article-title":"FDA approves erdafitinib for locally advanced or metastatic urothelial carcinoma","unstructured":"U.S. Food & Drug Administration. FDA approves erdafitinib for locally advanced or metastatic urothelial carcinoma.. Accessed February 6, 2024. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-erdafitinib-locally-advanced-or-metastatic-urothelial-carcinoma"}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/22\/4\/article-p216.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/22\/4\/article-p216.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/22\/4\/article-p216.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T08:40:38Z","timestamp":1715848838000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/22\/4\/article-p216.xml"}},"subtitle":["Featured Updates to the NCCN Guidelines"],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":47,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2024.0024","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5]]}}}